Nevro Corp. logo

Nevro Corp. (1N7)

Market Closed
31 Mar, 19:17
XSTU XSTU
5. 35
-0.05
-0.93%
- Market Cap
- P/E Ratio
0% Div Yield
0 Volume
-2.8 Eps
5.4
Previous Close
Day Range
5.3 5.35
Year Range
3.06 12.6
Earnings results expected in 30 days

Summary

1N7 closed Monday lower at €5.35, a decrease of 0.93% from Friday's close, completing a monthly decrease of -0.93% or €0.05. Over the past 12 months, 1N7 stock gained 51.13%.
1N7 is not paying dividends to its shareholders.
The last earnings report, released on Feb 19, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on May 05, 2025.
The stock of the company had never split.
The company's stock is traded on 5 different exchanges and in various currencies, with the primary listing on NYSE (USD).
Want to track 1N7 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

1N7 Chart

Chart

Empty chart
The chart has 2 Y axes displaying values, and values.
Loading, please wait...
End of interactive chart.

Nevro Corp. Dividends

1N7 is not paying dividends to its shareholders.

Nevro Corp. Earnings

5 May 2025 (30 Days) Date
-
Cons. EPS
-
EPS
19 Feb 2025 Date
-
Cons. EPS
-
EPS
11 Nov 2024 Date
-
Cons. EPS
-
EPS
30 Oct 2024 Date
-
Cons. EPS
-
EPS
7 Aug 2024 Date
-
Cons. EPS
-
EPS
1N7 is not paying dividends to its shareholders.
5 May 2025 (30 Days) Date
-
Cons. EPS
-
EPS
19 Feb 2025 Date
-
Cons. EPS
-
EPS
11 Nov 2024 Date
-
Cons. EPS
-
EPS
30 Oct 2024 Date
-
Cons. EPS
-
EPS
7 Aug 2024 Date
-
Cons. EPS
-
EPS

Nevro Corp. (1N7) FAQ

What is the stock price today?

The current price is €5.35.

On which exchange is it traded?

Nevro Corp. is listed on NYSE.

What is its stock symbol?

The ticker symbol is 1N7.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 0.

When is the next earnings date?

The next earnings report will release on May 05, 2025.

Has Nevro Corp. ever had a stock split?

Nevro Corp. had 0 splits and the recent split was on Nov 06, 2014.

Nevro Corp. Profile

Medical Devices Industry
Healthcare Sector
Mr. Roderick H. MacLeod CEO
XSTU Exchange
US64157F1030 ISIN
US Country
1,215 Employees
- Last Dividend
6 Nov 2014 Last Split
6 Nov 2014 IPO Date

Overview

Nevro Corp. is a distinguished entity within the medical device industry, focusing on the development and provision of innovative solutions for individuals suffering from chronic pain, both in the United States and internationally. Established in 2006 and having its headquarters in Redwood City, California, Nevro Corp. has set itself apart by offering advanced therapeutic products designed to alleviate chronic back and leg pain without the need for paresthesia. The company leverages its direct sales force alongside a network of sales agents and independent distributors to market its products, ensuring a wide reach to patients in need of their groundbreaking therapies.

Products and Services

Nevro Corp. offers a comprehensive range of products within its HFX spinal cord stimulation (SCS) platform and beyond, catering to the varied needs of patients suffering from chronic pain:

  • Senza SCS Implantable Pulse Generator (IPG) System: A cornerstone of Nevro Corp.'s offering, this neuromodulation system employs 10 kHz therapy to treat chronic back and leg pain without inducing paresthesia. The system is evidence-based, highlighting its effectiveness and reliability.
  • Senza II and Senza Omnia SCS IPG Systems: Building on the foundation laid by the original Senza system, these iterations offer enhanced features and flexibility, providing patients and healthcare professionals with additional options to tailor the treatment to individual needs.
  • Senza HFX iQ Platform: This platform represents a leap forward in patient-centered care, incorporating the HFX iQ implantable pulse generator, the HFX trial stimulator, and the HFX iQ patient remote. It is complemented by the HFX App, which allows for seamless patient control and wireless trialing, further personalizing the pain management experience.
  • Sacroiliac Joint Fusion Devices: Nevro Corp. extends its innovative approach to pain management to the sacroiliac joint, offering devices under the NevroV1, NevroFix, and NevroPro brands. These devices are designed to provide relief for patients with pain originating from the sacroiliac joint.
  • Surpass Surgical and Percutaneous Leads: Completing its portfolio, Nevro Corp. provides advanced surgical and percutaneous leads, essential components for the effective delivery of neuromodulation therapy. These leads are designed to be both durable and flexible, meeting the high standards required for chronic pain treatments.

Contact Information

Address: 1800 Bridge Parkway, Redwood City, CA, United States, 94065
Phone: 650 251 0005